Ronald Graf, MD
Endocrinology, Diabetes & Metabolism · Tacoma, WANPI 1144220583
Payments from drug & device makers
Across 855 payments — averaging $558.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$208K
- Eli Lilly$150K
- AstraZeneca$52K
- Amryt Pharma Holdings Ltd$27K
- Bayer$23K
- Merck$4K
- plus $14K from 38 others
Across 4 payments — averaging $150.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$488
- GSK$38
- Novo Nordisk$38
- AstraZeneca$38
What the payments were for
- Food & beverage$12,50899%
- Education$801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Macrilen$275
- EVENITY$233
- FREESTYLE LIBRE 3$151
- Minimed 670G System$125
- DEXCOM G6 TRANSMITTER$123
- Ozempic$107
- RYBELSUS$102
How this compares
$477,716 in reported general payments places this provider in the 90th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 154 | $201,453 |
| JardianceEmpagliflozin | 170 | $192,446 |
| TrulicityDulaglutide | 104 | $151,586 |
| MounjaroTirzepatide | 73 | $103,361 |
| FarxigaDapagliflozin Propanediol | 72 | $86,669 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $47,368 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 42 | $45,260 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 178 | $41,844 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 62 | $41,537 |
| Humalog Kwikpen U-100Insulin Lispro | 94 | $36,915 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $35,840 |
| Novolog FlexpenInsulin Aspart | 87 | $28,185 |
| KerendiaFinerenone | 31 | $26,606 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $24,214 |
| JanuviaSitagliptin Phosphate | 14 | $17,587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin N | $578 | $264,875206 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $1,735 | $221,162207 claims |
| Boehringer IngelheimJardiance, Glyxambi | $1,176 | $206,342190 claims |
| AstraZenecaFarxiga | $51,899 | $86,66972 claims |
| BayerKerendia | $22,750 | $26,60631 claims |
| MerckJanuvia | $4,084 | $17,58714 claims |
| AbbVieSynthroid | $207,721 | $7,63184 claims |
| Sanofi-aventis U.S. LLCLantus | $821 | $7,50030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Tacoma
- Gabriela Loperena OropezaTacoma$12K
- Ayesha JameelTacoma$9K
- Rebecca OverTacoma$6K
- Rani KulkarniTacoma$3K
- Ronald BrazgRenton$17.9M
- Frances BroylesSeattle$5.6M
- Leslie KlaffRenton$2.8M
- Carla GreenbaumSeattle$2.6M
- Irl HirschSeattle$2.4M
- William HagopianSeattle$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.